ACTA NEUROPHARMACOLOGICA ›› 2020, Vol. 10 ›› Issue (5): 38-42.DOI: 10.3969/j.issn.2095-1396.2020.05.009

Previous Articles     Next Articles

Current Situation and Prospect of Alzeimer’s Disease Treatment

WANG Si-yi,LI Xian-xiang,LIU Yi-zhou,DU Shuang,GE Chao,LIU Si-si   

  1. College of Pharmacy,Hebei North University,Hebei Key Laboratory of Neuropharmacology, Zhangjiakou,075000,China
  • Online:2020-10-26 Published:2020-10-26
  • Contact: 刘斯斯,女,硕士,讲师;研究方向:药物化学;E-mail:lsshbnu@163.com
  • About author:王思懿,女,药学学士;E-mail:2541020134@qq.com
  • Supported by:
    河北北方学院2021 年校级课程思政示范项目,河北省大学生创新创业项目(No.S202010092007,No.S202010092008, No.S202010092009)

Abstract:

Alzheimer’s disease is a degenerative neurological disease that is difficult to detect at its onset and gradually develops over time. The disease has become the fourth killer after heart disease,tumor,and stroke. This disease affects many systems of the human body,and the pathogenesis is more complicated and related to many factors. The main manifestations of the patients are memory,learning dysfunction and decline in daily life ability. The current treatment drugs mainly focus on improving clinical symptoms,and there are no effective drugs that can reverse or prevent the progression of the disease. This article reviews the incidence,pathogenic factors and related hypotheses of Alzheimer’s disease,and summarizes the current clinical treatment drugs such as cholinesterase inhibitors and N-methyl-D-aspartate receptors (NMDA) antagonist,with a view to provide a reference basis for future scientific research.

Key words: Alzheimer’s disease, AChE inhibitors, NMDA receptor antagonists